Generic Alyftrek 125mg/50mg/10mg tablets
NHS hospitals in England used £260,639,087 of indicative cost of Generic Alyftrek 125mg/50mg/10mg tablets in the 12 months to July 2026, about 1.0% of all hospital medicines spend. That is up 0.0% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Generic Alyftrek 125mg/50mg/10mg tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Generic Alyftrek 125mg/50mg/10mg tablets most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £27,209,790 |
| Guy's & St Thomas' Nhs Foundation Trust | £23,876,458 |
| Univ Hpl B/Ham Nhs Foundation Trust | £20,151,596 |
| Manchester University Nhs Ft | £19,184,133 |
| Univ Hpls Bristol Nhs Foundation Trust | £18,462,060 |
| Leeds Teaching Hpls Nhs Trust | £18,204,300 |
| Sheffield Teaching Hospitals Nhs Trust | £14,643,990 |
| King's College Hpl Nhs Foundation Trust | £13,467,960 |
| University Hpls North Midlands Nhs Trust | £13,153,815 |
| Frimley Health Nhs Foundation Trust | £9,376,020 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.